866-997-4948(US-Canada Toll Free)

United States Multiple Myeloma Drugs Market Report 2017

Published By :

QYResearch

Published Date : May 2017

Category :

Pharmaceutical

No. of Pages : 105 Pages

In this report, the United States Multiple Myeloma Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:
The West
Southwest
The Middle Atlantic
New England
The South
The Midwest
with sales (volume), revenue (value), market share and growth rate of Multiple Myeloma Drugs in these regions, from 2012 to 2022 (forecast).

United States Multiple Myeloma Drugs market competition by top manufacturers/players, with Multiple Myeloma Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
Amgen
Johnson & Johnson
Celgene
Takeda Pharmaceutical
Novartis
Daiichi Sankyo
Merck
AB Science
Teva
PharmaMar
Bristol Myers Squibb

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
Immunomodulatory Drugs (IMiDs)
Proteasome Inhibitors
Chemotherapy
Histone Deacetylase Inhibitor (HDAC Inhibitor)
Steroids (Corticosteroids)
Others
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Multiple Myeloma Drugs for each application, including
Targeted Therapy
Biologic Therapy
Chemotherapy
Others

If you have any special requirements, please let us know and we will offer you the report as you want.

Table of Contents

United States Multiple Myeloma Drugs Market Report 2017
1 Multiple Myeloma Drugs Overview
1.1 Product Overview and Scope of Multiple Myeloma Drugs
1.2 Classification of Multiple Myeloma Drugs by Product Category
1.2.1 United States Multiple Myeloma Drugs Market Size (Sales Volume) Comparison by Type (2012-2022)
1.2.2 United States Multiple Myeloma Drugs Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
1.2.3 Immunomodulatory Drugs (IMiDs)
1.2.4 Proteasome Inhibitors
1.2.5 Chemotherapy
1.2.6 Histone Deacetylase Inhibitor (HDAC Inhibitor)
1.2.7 Steroids (Corticosteroids)
1.2.8 Others
1.3 United States Multiple Myeloma Drugs Market by Application/End Users
1.3.1 United States Multiple Myeloma Drugs Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
1.3.2 Targeted Therapy
1.3.3 Biologic Therapy
1.3.4 Chemotherapy
1.3.5 Others
1.4 United States Multiple Myeloma Drugs Market by Region
1.4.1 United States Multiple Myeloma Drugs Market Size (Value) Comparison by Region (2012-2022)
1.4.2 The West Multiple Myeloma Drugs Status and Prospect (2012-2022)
1.4.3 Southwest Multiple Myeloma Drugs Status and Prospect (2012-2022)
1.4.4 The Middle Atlantic Multiple Myeloma Drugs Status and Prospect (2012-2022)
1.4.5 New England Multiple Myeloma Drugs Status and Prospect (2012-2022)
1.4.6 The South Multiple Myeloma Drugs Status and Prospect (2012-2022)
1.4.7 The Midwest Multiple Myeloma Drugs Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of Multiple Myeloma Drugs (2012-2022)
1.5.1 United States Multiple Myeloma Drugs Sales and Growth Rate (2012-2022)
1.5.2 United States Multiple Myeloma Drugs Revenue and Growth Rate (2012-2022)

2 United States Multiple Myeloma Drugs Market Competition by Players/Suppliers
2.1 United States Multiple Myeloma Drugs Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States Multiple Myeloma Drugs Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States Multiple Myeloma Drugs Average Price by Players/Suppliers (2012-2017)
2.4 United States Multiple Myeloma Drugs Market Competitive Situation and Trends
2.4.1 United States Multiple Myeloma Drugs Market Concentration Rate
2.4.2 United States Multiple Myeloma Drugs Market Share of Top 3 and Top 5 Players/Suppliers
2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Multiple Myeloma Drugs Manufacturing Base Distribution, Sales Area, Product Type

3 United States Multiple Myeloma Drugs Sales (Volume) and Revenue (Value) by Region (2012-2017)
3.1 United States Multiple Myeloma Drugs Sales and Market Share by Region (2012-2017)
3.2 United States Multiple Myeloma Drugs Revenue and Market Share by Region (2012-2017)
3.3 United States Multiple Myeloma Drugs Price by Region (2012-2017)

4 United States Multiple Myeloma Drugs Sales (Volume) and Revenue (Value) by Type (Product Category) (2012-2017)
4.1 United States Multiple Myeloma Drugs Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States Multiple Myeloma Drugs Revenue and Market Share by Type (2012-2017)
4.3 United States Multiple Myeloma Drugs Price by Type (2012-2017)
4.4 United States Multiple Myeloma Drugs Sales Growth Rate by Type (2012-2017)

5 United States Multiple Myeloma Drugs Sales (Volume) by Application (2012-2017)
5.1 United States Multiple Myeloma Drugs Sales and Market Share by Application (2012-2017)
5.2 United States Multiple Myeloma Drugs Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 United States Multiple Myeloma Drugs Players/Suppliers Profiles and Sales Data
6.1 Amgen
6.1.1 Company Basic Information, Manufacturing Base and Competitors
6.1.2 Multiple Myeloma Drugs Product Category, Application and Specification
6.1.2.1 Product A
6.1.2.2 Product B
6.1.3 Amgen Multiple Myeloma Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
6.1.4 Main Business/Business Overview
6.2 Johnson & Johnson
6.2.2 Multiple Myeloma Drugs Product Category, Application and Specification
6.2.2.1 Product A
6.2.2.2 Product B
6.2.3 Johnson & Johnson Multiple Myeloma Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
6.2.4 Main Business/Business Overview
6.3 Celgene
6.3.2 Multiple Myeloma Drugs Product Category, Application and Specification
6.3.2.1 Product A
6.3.2.2 Product B
6.3.3 Celgene Multiple Myeloma Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
6.3.4 Main Business/Business Overview
6.4 Takeda Pharmaceutical
6.4.2 Multiple Myeloma Drugs Product Category, Application and Specification
6.4.2.1 Product A
6.4.2.2 Product B
6.4.3 Takeda Pharmaceutical Multiple Myeloma Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
6.4.4 Main Business/Business Overview
6.5 Novartis
6.5.2 Multiple Myeloma Drugs Product Category, Application and Specification
6.5.2.1 Product A
6.5.2.2 Product B
6.5.3 Novartis Multiple Myeloma Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
6.5.4 Main Business/Business Overview
6.6 Daiichi Sankyo
6.6.2 Multiple Myeloma Drugs Product Category, Application and Specification
6.6.2.1 Product A
6.6.2.2 Product B
6.6.3 Daiichi Sankyo Multiple Myeloma Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
6.6.4 Main Business/Business Overview
6.7 Merck
6.7.2 Multiple Myeloma Drugs Product Category, Application and Specification
6.7.2.1 Product A
6.7.2.2 Product B
6.7.3 Merck Multiple Myeloma Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
6.7.4 Main Business/Business Overview
6.8 AB Science
6.8.2 Multiple Myeloma Drugs Product Category, Application and Specification
6.8.2.1 Product A
6.8.2.2 Product B
6.8.3 AB Science Multiple Myeloma Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
6.8.4 Main Business/Business Overview
6.9 Teva
6.9.2 Multiple Myeloma Drugs Product Category, Application and Specification
6.9.2.1 Product A
6.9.2.2 Product B
6.9.3 Teva Multiple Myeloma Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
6.9.4 Main Business/Business Overview
6.10 PharmaMar
6.10.2 Multiple Myeloma Drugs Product Category, Application and Specification
6.10.2.1 Product A
6.10.2.2 Product B
6.10.3 PharmaMar Multiple Myeloma Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
6.10.4 Main Business/Business Overview
6.11 Bristol Myers Squibb

7 Multiple Myeloma Drugs Manufacturing Cost Analysis
7.1 Multiple Myeloma Drugs Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Price Trend of Key Raw Materials
7.1.3 Key Suppliers of Raw Materials
7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.2.1 Raw Materials
7.2.2 Labor Cost
7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Multiple Myeloma Drugs

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
8.1 Multiple Myeloma Drugs Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Multiple Myeloma Drugs Major Manufacturers in 2016
8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
9.1 Marketing Channel
9.1.1 Direct Marketing
9.1.2 Indirect Marketing
9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
9.2.1 Pricing Strategy
9.2.2 Brand Strategy
9.2.3 Target Client
9.3 Distributors/Traders List

10 Market Effect Factors Analysis
10.1 Technology Progress/Risk
10.1.1 Substitutes Threat
10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 United States Multiple Myeloma Drugs Market Size (Value and Volume) Forecast (2017-2022)
11.1 United States Multiple Myeloma Drugs Sales Volume, Revenue Forecast (2017-2022)
11.2 United States Multiple Myeloma Drugs Sales Volume Forecast by Type (2017-2022)
11.3 United States Multiple Myeloma Drugs Sales Volume Forecast by Application (2017-2022)
11.4 United States Multiple Myeloma Drugs Sales Volume Forecast by Region (2017-2022)

12 Research Findings and Conclusion

13 Appendix
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer


List of Table

List of Tables and Figures

Figure Product Picture of Multiple Myeloma Drugs
Figure United States Multiple Myeloma Drugs Market Size (K MT) by Type (2012-2022)
Figure United States Multiple Myeloma Drugs Sales Volume Market Share by Type (Product Category) in 2016
Figure Immunomodulatory Drugs (IMiDs) Product Picture
Figure Proteasome Inhibitors Product Picture
Figure Chemotherapy Product Picture
Figure Histone Deacetylase Inhibitor (HDAC Inhibitor) Product Picture
Figure Steroids (Corticosteroids) Product Picture
Figure Others Product Picture
Figure United States Multiple Myeloma Drugs Market Size (K MT) by Application (2012-2022)
Figure United States Sales Market Share of Multiple Myeloma Drugs by Application in 2016
Figure Targeted Therapy Examples
Figure Biologic Therapy Examples
Figure Chemotherapy Examples
Figure Others Examples
Figure United States Multiple Myeloma Drugs Market Size (Million USD) by Region (2012-2022)
Figure The West Multiple Myeloma Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest Multiple Myeloma Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic Multiple Myeloma Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England Multiple Myeloma Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US Multiple Myeloma Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest Multiple Myeloma Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Multiple Myeloma Drugs Sales (K MT) and Growth Rate (2012-2022)
Figure United States Multiple Myeloma Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Multiple Myeloma Drugs Market Major Players Product Sales Volume (K MT) (2012-2017)
Table United States Multiple Myeloma Drugs Sales (K MT) of Key Players/Suppliers (2012-2017)
Table United States Multiple Myeloma Drugs Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States Multiple Myeloma Drugs Sales Share by Players/Suppliers
Figure 2017 United States Multiple Myeloma Drugs Sales Share by Players/Suppliers
Figure United States Multiple Myeloma Drugs Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States Multiple Myeloma Drugs Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States Multiple Myeloma Drugs Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States Multiple Myeloma Drugs Revenue Share by Players/Suppliers
Figure 2017 United States Multiple Myeloma Drugs Revenue Share by Players/Suppliers
Table United States Market Multiple Myeloma Drugs Average Price (USD/MT) of Key Players/Suppliers (2012-2017)
Figure United States Market Multiple Myeloma Drugs Average Price (USD/MT) of Key Players/Suppliers in 2016
Figure United States Multiple Myeloma Drugs Market Share of Top 3 Players/Suppliers
Figure United States Multiple Myeloma Drugs Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Multiple Myeloma Drugs Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Multiple Myeloma Drugs Product Category
Table United States Multiple Myeloma Drugs Sales (K MT) by Region (2012-2017)
Table United States Multiple Myeloma Drugs Sales Share by Region (2012-2017)
Figure United States Multiple Myeloma Drugs Sales Share by Region (2012-2017)
Figure United States Multiple Myeloma Drugs Sales Market Share by Region in 2016
Table United States Multiple Myeloma Drugs Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States Multiple Myeloma Drugs Revenue Share by Region (2012-2017)
Figure United States Multiple Myeloma Drugs Revenue Market Share by Region (2012-2017)
Figure United States Multiple Myeloma Drugs Revenue Market Share by Region in 2016
Table United States Multiple Myeloma Drugs Price (USD/MT) by Region (2012-2017)
Table United States Multiple Myeloma Drugs Sales (K MT) by Type (2012-2017)
Table United States Multiple Myeloma Drugs Sales Share by Type (2012-2017)
Figure United States Multiple Myeloma Drugs Sales Share by Type (2012-2017)
Figure United States Multiple Myeloma Drugs Sales Market Share by Type in 2016
Table United States Multiple Myeloma Drugs Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States Multiple Myeloma Drugs Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Multiple Myeloma Drugs by Type (2012-2017)
Figure Revenue Market Share of Multiple Myeloma Drugs by Type in 2016
Table United States Multiple Myeloma Drugs Price (USD/MT) by Types (2012-2017)
Figure United States Multiple Myeloma Drugs Sales Growth Rate by Type (2012-2017)
Table United States Multiple Myeloma Drugs Sales (K MT) by Application (2012-2017)
Table United States Multiple Myeloma Drugs Sales Market Share by Application (2012-2017)
Figure United States Multiple Myeloma Drugs Sales Market Share by Application (2012-2017)
Figure United States Multiple Myeloma Drugs Sales Market Share by Application in 2016
Table United States Multiple Myeloma Drugs Sales Growth Rate by Application (2012-2017)
Figure United States Multiple Myeloma Drugs Sales Growth Rate by Application (2012-2017)
Table Amgen Basic Information List
Table Amgen Multiple Myeloma Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Amgen Multiple Myeloma Drugs Sales Growth Rate (2012-2017)
Figure Amgen Multiple Myeloma Drugs Sales Market Share in United States (2012-2017)
Figure Amgen Multiple Myeloma Drugs Revenue Market Share in United States (2012-2017)
Table Johnson & Johnson Basic Information List
Table Johnson & Johnson Multiple Myeloma Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Johnson & Johnson Multiple Myeloma Drugs Sales Growth Rate (2012-2017)
Figure Johnson & Johnson Multiple Myeloma Drugs Sales Market Share in United States (2012-2017)
Figure Johnson & Johnson Multiple Myeloma Drugs Revenue Market Share in United States (2012-2017)
Table Celgene Basic Information List
Table Celgene Multiple Myeloma Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Celgene Multiple Myeloma Drugs Sales Growth Rate (2012-2017)
Figure Celgene Multiple Myeloma Drugs Sales Market Share in United States (2012-2017)
Figure Celgene Multiple Myeloma Drugs Revenue Market Share in United States (2012-2017)
Table Takeda Pharmaceutical Basic Information List
Table Takeda Pharmaceutical Multiple Myeloma Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Takeda Pharmaceutical Multiple Myeloma Drugs Sales Growth Rate (2012-2017)
Figure Takeda Pharmaceutical Multiple Myeloma Drugs Sales Market Share in United States (2012-2017)
Figure Takeda Pharmaceutical Multiple Myeloma Drugs Revenue Market Share in United States (2012-2017)
Table Novartis Basic Information List
Table Novartis Multiple Myeloma Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Novartis Multiple Myeloma Drugs Sales Growth Rate (2012-2017)
Figure Novartis Multiple Myeloma Drugs Sales Market Share in United States (2012-2017)
Figure Novartis Multiple Myeloma Drugs Revenue Market Share in United States (2012-2017)
Table Daiichi Sankyo Basic Information List
Table Daiichi Sankyo Multiple Myeloma Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Daiichi Sankyo Multiple Myeloma Drugs Sales Growth Rate (2012-2017)
Figure Daiichi Sankyo Multiple Myeloma Drugs Sales Market Share in United States (2012-2017)
Figure Daiichi Sankyo Multiple Myeloma Drugs Revenue Market Share in United States (2012-2017)
Table Merck Basic Information List
Table Merck Multiple Myeloma Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Merck Multiple Myeloma Drugs Sales Growth Rate (2012-2017)
Figure Merck Multiple Myeloma Drugs Sales Market Share in United States (2012-2017)
Figure Merck Multiple Myeloma Drugs Revenue Market Share in United States (2012-2017)
Table AB Science Basic Information List
Table AB Science Multiple Myeloma Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure AB Science Multiple Myeloma Drugs Sales Growth Rate (2012-2017)
Figure AB Science Multiple Myeloma Drugs Sales Market Share in United States (2012-2017)
Figure AB Science Multiple Myeloma Drugs Revenue Market Share in United States (2012-2017)
Table Teva Basic Information List
Table Teva Multiple Myeloma Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Teva Multiple Myeloma Drugs Sales Growth Rate (2012-2017)
Figure Teva Multiple Myeloma Drugs Sales Market Share in United States (2012-2017)
Figure Teva Multiple Myeloma Drugs Revenue Market Share in United States (2012-2017)
Table PharmaMar Basic Information List
Table PharmaMar Multiple Myeloma Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure PharmaMar Multiple Myeloma Drugs Sales Growth Rate (2012-2017)
Figure PharmaMar Multiple Myeloma Drugs Sales Market Share in United States (2012-2017)
Figure PharmaMar Multiple Myeloma Drugs Revenue Market Share in United States (2012-2017)
Table Bristol Myers Squibb Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Multiple Myeloma Drugs
Figure Manufacturing Process Analysis of Multiple Myeloma Drugs
Figure Multiple Myeloma Drugs Industrial Chain Analysis
Table Raw Materials Sources of Multiple Myeloma Drugs Major Players/Suppliers in 2016
Table Major Buyers of Multiple Myeloma Drugs
Table Distributors/Traders List
Figure United States Multiple Myeloma Drugs Sales Volume (K MT) and Growth Rate Forecast (2017-2022)
Figure United States Multiple Myeloma Drugs Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Multiple Myeloma Drugs Price (USD/MT) Trend Forecast (2017-2022)
Table United States Multiple Myeloma Drugs Sales Volume (K MT) Forecast by Type (2017-2022)
Figure United States Multiple Myeloma Drugs Sales Volume (K MT) Forecast by Type (2017-2022)
Figure United States Multiple Myeloma Drugs Sales Volume (K MT) Forecast by Type in 2022
Table United States Multiple Myeloma Drugs Sales Volume (K MT) Forecast by Application (2017-2022)
Figure United States Multiple Myeloma Drugs Sales Volume (K MT) Forecast by Application (2017-2022)
Figure United States Multiple Myeloma Drugs Sales Volume (K MT) Forecast by Application in 2022
Table United States Multiple Myeloma Drugs Sales Volume (K MT) Forecast by Region (2017-2022)
Table United States Multiple Myeloma Drugs Sales Volume Share Forecast by Region (2017-2022)
Figure United States Multiple Myeloma Drugs Sales Volume Share Forecast by Region (2017-2022)
Figure United States Multiple Myeloma Drugs Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *